Title of article :
Venom immunotherapy and pregnancy
Author/Authors :
Pałgan, Krzysztof Department of Allergology - Clinical Immunology and Internal Diseases - Ludwik Rydygier Collegium Medicum in Bydgoszcz - Nicolaus Copernicus University in Torun, Poland , Żbikowska-Götz, Magdalena Department of Allergology - Clinical Immunology and Internal Diseases - Ludwik Rydygier Collegium Medicum in Bydgoszcz - Nicolaus Copernicus University in Torun, Poland , Chrzaniecka, Elżbieta Department of Allergology - Clinical Immunology and Internal Diseases - Ludwik Rydygier Collegium Medicum in Bydgoszcz - Nicolaus Copernicus University in Torun, Poland , Bartuzi, Zbigniew Department of Allergology - Clinical Immunology and Internal Diseases - Ludwik Rydygier Collegium Medicum in Bydgoszcz - Nicolaus Copernicus University in Torun, Poland
Abstract :
Introductions
The efficiency of venom immunotherapy (VIT) has been well documented by many studies. However, the most important for VIT is safety, particularly for a pregnant woman and a fetus.
Aim
To establish the influence of continuation of VIT on pregnant women and offspring.
Material and methods
The 6 women became pregnant during a specific immunotherapy. We retrospectively analyzed the influence of the immunotherapy on any complications for the pregnant women and their infants.
Results
Of the 6 patients who participated in this study, four had hyperemesis gravidarum, nausea, and heartburn, and two of them had gestational diabetes mellitus symptoms, typical of pregnancy. The observation indicated that VIT was safe for the pregnant women and their offspring.
Conclusions
The VIT is an appropriate therapeutic method for most patients with severe anaphylactic reactions after a hymenoptera sting. The observation indicated that VIT is safe for pregnant women and for their infants.
Keywords :
venom immunotherapy , pregnancy
Journal title :
Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii
